Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Recruiting

Phase 3

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Sponsor:

Omeros Corporation

Code:

NCT03205995

Conditions

Thrombotic Microangiopathies

Atypical Hemolytic Uremic Syndrome

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

OMS721

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-21. This information was provided to ClinicalTrials.gov by Omeros Corporation on 2018-10-18.